111 related articles for article (PubMed ID: 32128940)
1. Conformationally constrained peptides for drug delivery.
Jerath G; Goyal R; Trivedi V; Santhoshkumar TR; Ramakrishnan V
J Pept Sci; 2020 Apr; 26(4-5):e3244. PubMed ID: 32128940
[TBL] [Abstract][Full Text] [Related]
2. Nonhemolytic Cell-Penetrating Peptides: Site Specific Introduction of Glutamine and Lysine Residues into the α-Helical Peptide Causes Deletion of Its Direct Membrane Disrupting Ability but Retention of Its Cell Penetrating Ability.
Kim S; Hyun S; Lee Y; Lee Y; Yu J
Biomacromolecules; 2016 Sep; 17(9):3007-15. PubMed ID: 27442521
[TBL] [Abstract][Full Text] [Related]
3. Induction of Au-methotrexate conjugates by sugar molecules: production, assembly mechanism, and bioassay studies.
Wang WY; Zhao XF; Ju XH; Liu P; Li J; Tang YW; Li SP; Li XD; Song FG
Int J Pharm; 2018 Mar; 538(1-2):65-78. PubMed ID: 29341908
[TBL] [Abstract][Full Text] [Related]
4. Anionic clay as the drug delivery vehicle: tumor targeting function of layered double hydroxide-methotrexate nanohybrid in C33A orthotopic cervical cancer model.
Choi G; Piao H; Alothman ZA; Vinu A; Yun CO; Choy JH
Int J Nanomedicine; 2016; 11():337-48. PubMed ID: 26855572
[TBL] [Abstract][Full Text] [Related]
5. Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells.
Szabó I; Orbán E; Schlosser G; Hudecz F; Bánóczi Z
Eur J Med Chem; 2016 Jun; 115():361-8. PubMed ID: 27031212
[TBL] [Abstract][Full Text] [Related]
6. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
Lindgren M; Rosenthal-Aizman K; Saar K; Eiríksdóttir E; Jiang Y; Sassian M; Ostlund P; Hällbrink M; Langel U
Biochem Pharmacol; 2006 Feb; 71(4):416-25. PubMed ID: 16376307
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional nanoparticles from albumin for stimuli-responsive efficient dual drug delivery.
Nosrati H; Abhari F; Charmi J; Davaran S; Danafar H
Bioorg Chem; 2019 Jul; 88():102959. PubMed ID: 31075743
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate).
Suksiriworapong J; Taresco V; Ivanov DP; Styliari ID; Sakchaisri K; Junyaprasert VB; Garnett MC
Colloids Surf B Biointerfaces; 2018 Jul; 167():115-125. PubMed ID: 29631222
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and pH-controllable methotrexate release from biocompatible polymer/silica nanocomposite for anticancer drug delivery.
Rasouli S; Davaran S; Rasouli F; Mahkam M; Salehi R
Drug Deliv; 2014 May; 21(3):155-63. PubMed ID: 24107075
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.
Ofner CM; Pica K; Bowman BJ; Chen CS
Int J Pharm; 2006 Feb; 308(1-2):90-9. PubMed ID: 16361072
[TBL] [Abstract][Full Text] [Related]
11. Effects of N-terminal and C-terminal modification on cytotoxicity and cellular uptake of amphiphilic cell penetrating peptides.
Soleymani-Goloujeh M; Nokhodchi A; Niazi M; Najafi-Hajivar S; Shahbazi-Mojarrad J; Zarghami N; Zakeri-Milani P; Mohammadi A; Karimi M; Valizadeh H
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):91-103. PubMed ID: 29258339
[TBL] [Abstract][Full Text] [Related]
12. Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.
Böhme D; Beck-Sickinger AG
ChemMedChem; 2015 May; 10(5):804-14. PubMed ID: 25914147
[TBL] [Abstract][Full Text] [Related]
13. Lipophilic methotrexate conjugates with antitumor activity.
Pignatello R; Spampinato G; Sorrenti V; Di Giacomo C; Vicari L; McGuire JJ; Russell CA; Puglisi G; Toth I
Eur J Pharm Sci; 2000 May; 10(3):237-45. PubMed ID: 10767601
[TBL] [Abstract][Full Text] [Related]
14. Controlled release of methotrexate from w/o microemulsion and its in vitro antitumor activity.
Karasulu HY; Karabulut B; Göker E; Güneri T; Gabor F
Drug Deliv; 2007 Apr; 14(4):225-33. PubMed ID: 17497355
[TBL] [Abstract][Full Text] [Related]
15. Construction of pH-sensitive lysozyme/pectin nanogel for tumor methotrexate delivery.
Lin L; Xu W; Liang H; He L; Liu S; Li Y; Li B; Chen Y
Colloids Surf B Biointerfaces; 2015 Feb; 126():459-66. PubMed ID: 25601095
[TBL] [Abstract][Full Text] [Related]
16. Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy.
Li Y; Zhang H; Chen Y; Ma J; Lin J; Zhang Y; Fan Z; Su G; Xie L; Zhu X; Hou Z
Biomater Sci; 2018 Jun; 6(7):1818-1833. PubMed ID: 29785434
[TBL] [Abstract][Full Text] [Related]
17. Delivery of Small Molecules by Syndiotactic Peptides for Breast Cancer Therapy.
Jerath G; Darvin P; Christian Y; Trivedi V; Kumar TRS; Ramakrishnan V
Mol Pharm; 2022 Aug; 19(8):2877-2887. PubMed ID: 35839086
[TBL] [Abstract][Full Text] [Related]
18. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
19. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics.
Garg NK; Singh B; Jain A; Nirbhavane P; Sharma R; Tyagi RK; Kushwah V; Jain S; Katare OP
Colloids Surf B Biointerfaces; 2016 Oct; 146():114-26. PubMed ID: 27268228
[TBL] [Abstract][Full Text] [Related]
20. Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect.
Jia M; Li Y; Yang X; Huang Y; Wu H; Huang Y; Lin J; Li Y; Hou Z; Zhang Q
ACS Appl Mater Interfaces; 2014 Jul; 6(14):11413-23. PubMed ID: 24977925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
